Article Sidebar

PDF (Tiếng Việt)
Published: 2024-05-15
Abstract Views: 90
Views PDF (Tiếng Việt): 47
DOI: https://doi.org/10.52163/yhc.v65iCD3.1134
Issue
Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương
Section
Articles
How to Cite
Linh, L. T. ., Lượng, Đinh V. ., Quảng, L. V. ., Anh, . N. H. ., Thư, L. N. M. ., Anh, H. H. ., My, N. D. ., Nhung, N. V. ., Trang, N. T. ., Hiếu, D. H. ., & Bộ, D. D. . (2024). 37. CLINICAL FEATURES, SUBCLINICAL CHARACTERISTICS AND RESULTS OF TARGET TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS WITH DOUBLE MUTATIONS OF THE EGFR GENE PERIOD 2019-2023. Vietnam Journal of Community Medicine, 65(CĐ 3 - Bệnh viện Phổi Trung ương). https://doi.org/10.52163/yhc.v65iCD3.1134

37. CLINICAL FEATURES, SUBCLINICAL CHARACTERISTICS AND RESULTS OF TARGET TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS WITH DOUBLE MUTATIONS OF THE EGFR GENE PERIOD 2019-2023

Le Tu Linh1,2, Dinh Van Luong1,2, Le Van Quang2,3, Nguyen Hoang Anh2, Le Ngoc Minh Thu2, Hoang Huy Anh2, Nguyen Dieu My2, Nguyen Viet Nhung4, Nguyen Thi Trang2, Duong Huu Hieu1, Duong Danh Bo1
1 National Lung Hospital
2 Hanoi Medical University
3 K Hospital
4 University of Medicine and Pharmacy - Hanoi National University

Main Article Content

Abstract

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) administered as initial therapy enhance the quality of life for individuals diagnosed with EGFR mutation-sensitive non-small cell lung cancer (NSCLC). Our investigation focused on evaluating treatment outcomes among patients with EGFR-mutant NSCLC who exhibit concurrent gene alterations, aiming to ascertain their predictive significance regarding response to EGFR-TKIs treatment.


Materials and Methods: A retrospective cohort study was conducted the next gene sequencing (NGS) data from January 2019 to Jun 2023. All patients were categorized into two groups: One comprising individuals with a single EGFR mutation (group 1), and the other consisting of patients with concurrent EGFR mutations (group 2).


Results: 109 patients with EGFR mutation showed 72 patients had partial responses (66.1%), one had complete response (0.9%) and 17 patients had stable disease (15.6%); 19 patients had progressive disease (17.4%). The ORR was 67% and DCR was 82.6%. The PFS in the group with single EGFR mutation and concurrent gene alterations group were 15.03 months (CI 95%: 13.17-16.89) and 11.00 months (CI 95%: 9.95-12.05) (p= 0.001). Among the 43 patients with concomitant mutations, patients with ALK mutation had the longest PFS (13.43 months), followed by other PIK3CA (11.00 months) and the lowest PFS was MET application (4.77 months).


Conclusion: This study has demonstrated the concurrent gene alterations in some patients with EGFR mutations, which leads to reduced outcome of EGFR-TKIs. Patients carrying KRAS, BRAF, ROS1, or MET mutations are considered to have less predictive value for positive treatment outcomes.

Article Details

Keywords

Epidermal growth factor receptor (EGFR), concomitant genes, treatment outcome.

References

[1] M. Jakopovic, A. Thomas, S. Balasubramaniam
et al., Targeting the Epigenome in Lung Cancer:
Expanding Approaches to Epigenetic Therapy,
Front. Oncol., vol. 3, p. 261, Oct. 2013,
[2] Y. Zhao et al., Clinical Management of NonSmall
Cell Lung Cancer with Concomitant
EGFR Mutations and ALK Rearrangements:
Efficacy of EGFR Tyrosine Kinase Inhibitors
and Crizotinib, Target. Oncol., vol. 14, no. 2, pp.
169–178, Apr. 2019, doi: 10.1007/s11523-019-
00628-6.
[3] S. Li et al., Coexistence of EGFR with KRAS,
or BRAF, or PIK3CA somatic mutations in lung
cancer: A comprehensive mutation profiling
from 5125 Chinese cohorts, Br. J. Cancer, vol.
110, no. 11, pp. 2812–2820, May 2014, doi:
10.1038/bjc.2014.210.
[4] L. Beer et al., Comparison of RECIST, iRECIST,
and PERCIST for the Evaluation of Response to
PD-1/PD-L1 Blockade Therapy in Patients With
Non-Small Cell Lung Cancer, Clin. Nucl. Med.,
vol. 44, no. 7, pp. 535–543, Jul. 2019,
[5] S. Sato et al., Impact of Concurrent Genomic
Alterations Detected by Comprehensive Genomic
Sequencing on Clinical Outcomes in East-Asian
Patients with EGFR-Mutated Lung Adenocarcinoma,
Sci. Rep., vol. 8, no. 1, p. 1005, Jan. 2018,
doi: 10.1038/s41598-017-18560-y.
[6] J. Fan et al., Concomitant EGFR mutation and
ALK rearrangement in multifocal lung adenocarcinoma:
A case report, Diagn. Pathol., vol.
15, no. 1, p. 42, May 2020, doi: 10.1186/s13000-
020-00969-1.
[7] N.-N. Lou et al., Clinical outcomes of advanced
non-small-cell lung cancer patients with EGFR
mutation, ALK rearrangement and EGFR/ALK
co-alterations, Oncotarget, vol. 7, no. 40, pp.
65185–65195, Oct. 2016, doi: 10.18632/oncotarget.11218.
[8] S. Li et al., Coexistence of EGFR with KRAS,
or BRAF, or PIK3CA somatic mutations in lung
cancer: A comprehensive mutation profiling
from 5125 Chinese cohorts, Br. J. Cancer, vol.
110, no. 11, pp. 2812–2820, May 2014, doi:
10.1038/bjc.2014.210.
[9] H. Liang et al., Concomitant Mutations in EGFR
19Del/L858R Mutation and Their Association
with Response to EGFR-TKIs in NSCLC Patients,
Cancer Manag. Res., vol. 12, pp. 8653–8662, 2020,
[10] J. A. Engelman et al., MET amplification leads
to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, vol. 316, no.
5827, pp. 1039–1043, May 2007, doi: 10.1126/
science.1141478.
[11] M. Sun et al., Combined targeting of EGFR and
BRAF triggers regression of osimertinib resistance by
using osimertinib and vemurafenib concurrently in
a patient with heterogeneity between
different lesions, Thorac. Cancer, vol. 13, no.
3, pp. 514–516, Feb. 2022, doi: 10.1111/1759-
7714.14295.
[12] M. Chen et al., Concurrent Driver Gene Mutations
as Negative Predictive Factors in Epidermal Growth
Factor Receptor-Positive NonSmall Cell Lung Cancer,
EBioMedicine, vol. 42,pp. 304–310, Apr. 2019,
[13] M. Chevallier, P. Tsantoulis, A. Addeo et al., Influence
of Concurrent Mutations on Overall Survival in EGFR-
mutated Non-small Cell Lung Cancer, Cancer Genomics
Proteomics, vol. 17,no. 5, pp. 597–603, 2020,